Opinion

Video

CodeBreaK 200: Sotorasib in Second Line KRAS G12C-Mutated NSCLC

Dr. Sabari and Dr. Garon discuss second line sotorasib and the results of the CodeBreaK 200 study, highlighting the recent FDA oncologic drugs advisory committee (ODAC) and their assessment of the study results.

Related Videos
3 experts are featured in this series.
3 experts are featured in this series.
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
2 expert is featured in this series.
2 expert is featured in this series.